The Alzheimer’s Prevention Registry recently enrolled the 40,000th volunteer to take part in a major study on Alzheimer’s disease that will be conducted by Banner Alzheimer’s Institute (BAI) in collaboration with other organizations and scientists. The online gateway’s main purpose is to accelerate research by connecting healthy people who are committed to…
News
Even though Alzheimer’s disease is typically only diagnosed in the elderly population, the disease is already present in the brain long before symptoms become visible. Researchers at University of Stanford believe they have found a few promising signs that indicate the early presence of the disease in patients as a result of observing the development…
A research team from the University of Exeter Medical School and King’s College London has uncovered strong evidence of neurological epigenetic changes leading to Alzheimer Disease (AD) development. There are over 26 million people affected by AD worldwide, a chronic neurodegenerative disorder characterized by progressive neuropathology and cognitive decline. Despite…
Almost two-thirds of more than five million Americans currently living with Alzheimer’s disease (AD) are women, and American women are twice as likely to die of Alzheimer’s disease as they are from breast cancer. According to the Alzheimer’s Association, someone in America develops Alzheimer’s every 67 seconds, and in…
A new study by researchers at the Stanford University School of Medicine has found that some constituent or agent in the blood of young mice when infused to the bloodsteams of old mice has the ability to restore deteriorating mental capabilities. The scientists suggest that if the same phenomenon…
An intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer’s disease and dementia. The first results of the…
Researchers from the Blanchette Rockefeller Neuroscience Institute (BRNI) have gathered evidence of the possible role of protein kinase C epsilon (PKCe) in the treatment of Alzheimer’s disease (AD). The news was recently announced by Neurotrope, a pharmaceutical company collaborating with BRNI in the development of bryostatin, a potent modulator of PKCe,…
Researchers at Brigham and Women’s Hospital (BWH) continue to make important contributions to the advancement of further understanding the underlying causes of Alzheimer’s disease. After last week’s announcement that BWH scientists have determined that decreased brain activity is linked to a decline in the ability to conduct daily tasks…
Independent research by the Home Instead Senior Care network of seniors, adult children, senior care and legal professionals provides new insights into the dynamics of the conversations that do and do not take place between Baby Boomers and their aging parents. A new survey finds approximately 80 million Americans…
Individuals with frontotemporal degeneration (FTD) may soon benefit from research priorities directed toward curing Alzheimer’s disease and other forms of dementia. The Association of Frontotemporal Degeneration (AFTD) broke word of plans to formally include FTD in national research priorities by the year 2025. According to AFTD Executive Director Susan…
Recent Posts
- FDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi February 2, 2026
- FDA decision on AXS-05 for Alzheimer’s agitation expected April 30 January 6, 2026
- Oral semaglutide fails to slow Alzheimer’s in pair of clinical trials December 2, 2025
- Canada gives conditional OK to early Alzheimer’s drug Leqembi November 4, 2025
- Kisunla approval offers new option to treat early Alzheimer’s in Europe October 3, 2025